'Vyndamax' fails reimbursement listing once again
By Eo, Yun-Ho | translator Alice Kang
21.10.26 16:39:36
가나다라
0
Applied for RSA after failing to receive essential drug designation, but was determined inappropriate at subcommittee
Estimated to be due to fiscal impact… HCPs “Discussions should be held between GOV·pharmaceutical industy in consideration of the patients”
The new transthyretin amyloid cardiomyopathy (ATTR-CM) drug, 'Vyndamax,’ is suffering hardships in its process of being listed for insurance benefit.
According to industry sources, the application Pfizer Korea submitted for the reimbursement of its new ATTR-CM drug, Vyndamax (tafamidis 61mg), was unable to pass the insurance benefit standard subcommittee.
After the company failed to receive designation as an essential drug earlier this year, the company had applied for reimbursement once again through the Risk Sharing Agreement (RSA) scheme. Being deemed inappropriate after submitting data for PE evaluation, reimbursement of Vyndamax is facing difficulties.
The pro
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)